Merck & Co., Inc. anticipates making a windfall from sales of molnupiravir to treat COVID-19, forecasting that sales of the antiviral should total $5bn-$7bn globally through 2022, the company said during its third quarter sales and earnings call on 28 October. Merck expects to realize $500m-$1bn of that this year, assuming the product receives an Emergency Use Authorization (EUA) from the US Food and Drug Administration in December.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?